Genoskin is a pioneering biotechnology company that leverages biological, non-clinical immunoprofiling testing to reduce the risks associated with human therapeutic drugs, vaccines, medical devices, and cosmetics development, by providing earlier access to higher quality human data during the drug development process. We are committed to ethical and sustainable practices by offering reliable alternatives to experimentation using animal models.

Genoskin’s human skin platforms use biostabilized and immunocompetent ex vivo human skin from diverse donor populations to evaluate the efficacy and toxicity of injectable biotherapeutics. These human skin models are highly representative of in vivo conditions, allowing for more accurate and reliable biological testing of drug candidates using various cellular and molecular biology assays. We employ advanced analytical technologies such as next-generation transcriptomics and multiplexed proteomics, combined with machine-learning and artificial intelligence to generate actionable, consistent human data to accelerate the development of human therapeutics.